VIPR1 Inhibitor Delivery for Auditory Cortex Interneuron Excitability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies fail to effectively enhance auditory cortex interneuron excitability and improve pitch-discrimination acuity, which is crucial for musicality and language processing.
Innovation Solution
Inhibiting the expression or activity of Vasoactive Intestinal Peptide Receptor 1 (VIPR1) using VIPR1 peptide antagonists or inhibitory RNA molecules to increase the excitability of auditory cortex interneurons.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If VIPR1 activity is inhibited to increase auditory cortex interneuron excitability, then pitch-discrimination acuity is improved, but side effects may occur in other physiological systems regulated by VIPR1
Solution Approach 1:
The patent applies local quality by delivering VIPR1 inhibition specifically to the auditory cortex using AAV viral vectors with neuronal promoters, ensuring that VIPR1 inhibition occurs only in the target brain region and not systemically, thereby improving pitch discrimination without causing widespread side effects
Solution Approach 2:
The patent uses AAV viral vectors as intermediaries to deliver shRNA molecules that inhibit VIPR1 expression. This intermediary approach allows for controlled, localized delivery of the inhibitory mechanism to auditory cortex neurons, enabling precise modulation of VIPR1 activity in the target tissue
2Measurement precision
If VIPR1 expression is inhibited using inhibitory RNA molecules, then auditory cortex interneuron excitability increases, but delivery and targeting precision become challenging
Solution Approach 1:
The patent employs AAV viral vectors as intermediary carriers to deliver shRNA molecules into auditory cortex neurons. This intermediary system simplifies the delivery process by using the virus's natural tropism and replication machinery to achieve targeted gene silencing without requiring complex non-viral delivery systems
Solution Approach 2:
The patent changes the molecular state of VIPR1 by introducing shRNA that causes degradation of VIPR1 mRNA, thereby reducing VIPR1 protein expression levels. This parameter change (from full expression to reduced expression) achieves the desired increase in interneuron excitability while maintaining cellular health
3Measurement precision
If VIPR1 activity is blocked to enhance GABAergic interneuron function, then frequency discrimination improves, but overall neuronal network stability may be affected
Solution Approach 1:
The patent applies local quality by restricting VIPR1 inhibition specifically to GABAergic interneurons in the auditory cortex through cell-type-specific promoter-driven shRNA expression. This localized approach enhances frequency discrimination in these specific neurons while preserving VIPR1 function in other neuronal populations that maintain network stability
Solution Approach 2:
The patent implements partial action by reducing VIPR1 expression to a level that sufficiently enhances interneuron excitability for improved frequency discrimination, rather than complete knockout. This partial inhibition achieves the desired functional improvement while maintaining enough VIPR1 activity to preserve neuronal network stability
Data Source
AI summary
Methods for increasing auditory cortex interneuron excitability and improving auditory perception, in particular pitch-discrimination acuity, are provided, which include the use of a Vasoactive Intestinal Peptide Receptor 1 (VIPR1) inhibitor.